何立儒副主任医师
中山大学附属肿瘤医院放疗科
工作与学习经历：2007年毕业于中山大学临床医学七年制;主要从事泌尿系统肿瘤和胸部肿瘤的研究和临床治疗。2011年入选中山大学肿瘤防治中心优才计划培养对象;2013年以国家公派身份到美国M.D.Anderson癌症中心进修1年，针对泌尿系统和胸部肿瘤放疗的前沿技术进行了系统学习;2015年担任我院前列腺癌MDT团队放疗会诊专家;同年获聘中国抗癌协会泌尿肿瘤系统专业委员会青年委员。 研究方向与业绩：主要从事泌尿系统肿瘤和胸部肿瘤的研究和临床治疗。先后发表SCI论文30余篇，其中以第一作者和并列第一作者身份发表SCI论文13篇(5分以上7篇)。作为项目负责人获得国家自然科学基金1项，中山大学优秀人才项目1项;作为主要成员参加国家自然科学基金2项以及广东省级科研基金7项。 主要科研项目 (1) 国家自然科学基金(青年项目)：AIB1在肺腺癌转移中的作用及分子机制(81201842)。24万元。2013.1～2015.12。项目负责人。 (2) 中山大学肿瘤防治中心优秀青年人才培养计划基金：AIB1在食管鳞癌放射抵抗中的作用及分子机制。5万元/年。2011.1～2015.12。项目负责人。 (3) 国家自然科学基金(青年项目)：miR-130b在肝细胞癌发病中的作用及其表达调控机制(81101863)。23万元。2012.1～2014.12。第二申请人。 门诊时间：每周一下午 电话：020-87342250 主要代表作 (1) He LR, Zhao HY, Li BK, Zhang LJ, Liu MZ, Kung HF, Guan XY, Bian XW, Zeng YX, Xie D. Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients. Ann Oncol. 2010;21(8):1675-81. (2) He LR, Ma NF, Chen JW, Li BK, Guan XY, Liu MZ, Xie D. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival. Oncotarget. 2015; 6(31):31181-90. (3) He L, Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z, Lin SH. Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol. 2014; 9(9):1398-405 (4) He LR, Zhao HY, Li BK, Liu YH, Liu MZ, Guan XY, Bian XW, Zeng YX, Xie D. Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients. Int J Cancer. 2011; 129(1):143-50. (5) He LR, Liu MZ, Li BK, Jia WH, Zhang Y, Liao YJ, Chen YC, Zhang LJ, Guan XY, Zeng YX, Kung HF, Xie D. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer. 2010;127(1):138-47. (6) He LR, Liu MZ, Li BK, Rao HL, Deng HX, Guan XY, Zeng YX, Xie D. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009;100(9):1591-6. ( (7) He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Zhang LJ, Guan XY, Zeng YX, Xie D. Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma. Cancer Sci. 2009;100(12):2354-60. (8) He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Guan XY, Zeng YX, Xie D. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer. 2009;9:461. (9) He LR, Qiao W, Liao ZX, Komaki R, Ho L, Hofstetter WL, Lin SH. Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma. BMC Cancer. 2015; 15:1095. (10) Qian D, Zhang B, He LR(并列第一作者), Cai MY, Mai SJ, Liao YJ, Liu YH, Lin Marie C., Bian XW, Zeng YX, Huang JJ, Kung HF, and XieD. The Telomere/Telomerase Binding Factor PinX1 is a New Target to Improve the Radiotherapy Effect of Esophageal Squamous Cell Carcinomas. J Pathol. 2013; 229(5):765-74. (11) Tian XP, Qian D, He LR(并列第一作者), Huang H, Mai SJ, Li CP, Huang XX, Cai MY, Liao YJ, Kung HF, Zeng YX, Xie D. The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas. Cancer Lett. 2014; 353(1):104-14. (12) Liu JY, Qian D, He LR(并列第一作者), Li YH, Liao YJ, Mai SJ, Tian XP, Liu YH, Zhang JX, Kung HF, Zeng YX, Zhou FJ, Xie D. PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway. Mol Cancer. 2013; 12(1):148. (13) Cao X, He LR (并列第一作者), Xie FY, Chen YF, Wen ZS. Factors determining the survival of nasopharyngeal carcinoma with lung metastasis alone: does combined modality treatment benefit? BMC Cancer. 2011; 11:370. (14) 何立儒, 刘孟忠. 前列腺癌的外照射放疗进展. 国际肿瘤学杂志. 2008; 35(7):533-6.
